GlassScriptPhysician profile
Erin Allise Vavro
NPI 1881186005
$1,846.03
in general payments reported to CMS, 2019-2025
19 companies · $1,054 in 2025
The $1,054 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $38.39 · 2023: $236 · 2024: $517 · 2025: $1,054.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,807.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $479.90 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Exact Sciences Corporation | $234.07 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $182.76 | 2024-2025 | Airsupra, Breztri |
| Amgen INC. | $153.67 | 2024-2025 | Repatha, Otezla, Krystexxa |
| Lilly USA, LLC | $130.56 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $124.91 | 2023-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Pfizer INC. | $94.69 | 2024-2025 | |
| Glaxosmithkline, LLC. | $80.99 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.32 | 2024-2025 | Xifaxan |
| Axsome Therapeutics, INC. | $49.93 | 2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $44.88 | 2025 | Qelbree |
| Dynavax Technologies Corporation | $38.72 | 2022-2025 | Heplisav-B |
| Phathom Pharmaceuticals, INC. | $35.59 | 2025 | Voquezna |
| Agios Pharmaceuticals, INC. | $27.94 | 2025 | Pyrukynd |
| Abbott Laboratories | $27.54 | 2024 | Freestyle Libre 3 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $17.87 | 2025 | |
| Abbvie INC. | $17.17 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.68 | 2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $15.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Vavro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.